Urologic Cancer Program


The Penn Difference

Innovative Research...Advanced Medicine...Service Excellence

  • Nationally recognized experts
  • Multidisciplinary evaluation
  • Advanced diagnostic testing, treatments and technologies
  • Coordinated care
  • Support services
  • A reputation for sensitivity and responsiveness
  • Personalized attention
  • Innovative clinical trials
  • The backing of an outstanding major research program with immediate translation to patient care

What sets Penn’s Urologic Cancers Program apart?

Penn's Abramson Cancer Center has one of the nation's leading programs for the diagnosis and treatment of urologic cancers. Penn specialists are at the forefront of treating patients with cancers of the prostate, bladder, kidney and testes.

It is this relentless pursuit for the very best clinical outcome and quality of life that drives Penn’s Urologic Cancers Program.

Our Urologic Cancers program is distinguished in many ways, including:

  • Created the device that provides the most precise image of the prostate gland currently available to more accurately stage prostate tumors.
  • Our urologists are world renowned in cutting edge surgical techniques, such as nerve-sparring and robotically-assisted prostatectomy.
  • Pioneers in the use of robotically-assisted urologic surgery.
  • Developed surgical treatment techniques to preserve urinary and sexual function.
  • As national leaders in the field of chemoradiation, our physicians have pioneered chemotherapy regimens that have become the national standard of care.
  • Perform more prostatectomies, as well as,transurethral and testicular procedures than any other Greater Philadelphia hospital.
  • Made significant contributions to the knowledge base in every area of urology including cancer, incontinence, male sexual health, and male infertility.
  • Is a leader in interdisciplinary cancer care, including the establishment of a team approach that includes designated urologists, as well as, radiation and medical oncologists.
  • Focus on coordination of care and availability of complementary and alternative medicine.
  • In the mid 1970’s, carried out the first radioactive seed treatment for prostate cancer in Philadelphia.
  • U.S. News & World Report rank Penn’s urology program the highest in the region.
  • An $8.5 million grant awarded to our Cancer Epidemiology and Risk Reduction Program from the National Cancer Institute to initiate studies to understand why African Americans have poorer outcomes when they are diagnosed with prostate cancer.
  • Many of the physicians from Penn’s Urologic Cancer Program are recognized repeatedly by Best Doctors in America, and Philadelphia Magazine's Top Docs issue.